127 related articles for article (PubMed ID: 35142223)
21. Complement protein C1q stimulates hyaluronic acid degradation
Balduit A; Vidergar R; Zacchi P; Mangogna A; Agostinis C; Grandolfo M; Bottin C; Salton F; Confalonieri P; Rocca A; Zanconati F; Confalonieri M; Kishore U; Ghebrehiwet B; Bulla R
Front Immunol; 2023; 14():1151194. PubMed ID: 37334363
[TBL] [Abstract][Full Text] [Related]
22. Hyaluronan nanogel co-loaded with chloroquine to enhance intracellular cisplatin delivery through lysosomal permeabilization and lysophagy inhibition.
Gao M; Deng H; Zhang Y; Wang H; Liu R; Hou W; Zhang W
Carbohydr Polym; 2024 Jan; 323():121415. PubMed ID: 37940248
[TBL] [Abstract][Full Text] [Related]
23. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
Yamaji M; Ota A; Wahiduzzaman M; Karnan S; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Haniuda M
Cancer Med; 2017 Nov; 6(11):2646-2659. PubMed ID: 28960945
[TBL] [Abstract][Full Text] [Related]
24. Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors.
Wei X; Senanayake TH; Warren G; Vinogradov SV
Bioconjug Chem; 2013 Apr; 24(4):658-68. PubMed ID: 23547842
[TBL] [Abstract][Full Text] [Related]
25. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
Lam SK; Li YY; Xu S; Leung LL; U KP; Zheng YF; Cheng PN; Ho JC
Respir Res; 2017 May; 18(1):80. PubMed ID: 28464918
[TBL] [Abstract][Full Text] [Related]
26. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.
Ikuta K; Yano S; Trung VT; Hanibuchi M; Goto H; Li Q; Wang W; Yamada T; Ogino H; Kakiuchi S; Uehara H; Sekido Y; Uenaka T; Nishioka Y; Sone S
Clin Cancer Res; 2009 Dec; 15(23):7229-37. PubMed ID: 19934291
[TBL] [Abstract][Full Text] [Related]
27. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
Cho H; Matsumoto S; Fujita Y; Kuroda A; Menju T; Sonobe M; Kondo N; Torii I; Nakano T; Lara PN; Gandara DR; Date H; Hasegawa S
J Thorac Oncol; 2017 Mar; 12(3):477-490. PubMed ID: 27867002
[TBL] [Abstract][Full Text] [Related]
28. SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma.
Salaroglio IC; Belisario DC; Bironzo P; Ananthanarayanan P; Ricci L; Digiovanni S; Fontana S; Napoli F; Sandri A; Facolmatà C; Libener R; Comunanza V; Grosso F; Gazzano E; Leo F; Taulli R; Bussolino F; Righi L; Papotti MG; Novello S; Scagliotti GV; Riganti C; Kopecka J
J Exp Clin Cancer Res; 2022 Feb; 41(1):75. PubMed ID: 35197103
[TBL] [Abstract][Full Text] [Related]
29. Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model.
Abu Lila AS; Kato C; Fukushima M; Huang CL; Wada H; Ishida T
Int J Oncol; 2016 Apr; 48(4):1399-407. PubMed ID: 26847426
[TBL] [Abstract][Full Text] [Related]
30. The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.
Oguh-Olayinka L; Agarwal V; Ranatunge D; Campbell A; Laufer S; Cawkwell L; Lind MJ
Pathol Oncol Res; 2020 Apr; 26(2):985-995. PubMed ID: 30941737
[TBL] [Abstract][Full Text] [Related]
31. Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma.
Kitamura A; Matsushita K; Takiguchi Y; Shimada H; Tada Y; Yamanaka M; Hiroshima K; Tagawa M; Tomonaga T; Matsubara H; Inoue M; Hasegawa M; Sato Y; Levens D; Tatsumi K; Nomura F
Cancer Sci; 2011 Jul; 102(7):1366-73. PubMed ID: 21435101
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma.
Takayama Y; Hattori N; Hamada H; Masuda T; Omori K; Akita S; Iwamoto H; Fujitaka K; Kohno N
Cancer Res; 2016 Jun; 76(11):3285-94. PubMed ID: 27197170
[TBL] [Abstract][Full Text] [Related]
33. Intraperitoneal Administration of a Cisplatin-Loaded Nanogel through a Hybrid System Containing an Alginic Acid-Based Nanogel and an
Yamaguchi K; Hiraike O; Iwaki H; Matsumiya K; Nakamura N; Sone K; Ohta S; Osuga Y; Ito T
Mol Pharm; 2021 Nov; 18(11):4090-4098. PubMed ID: 34662129
[TBL] [Abstract][Full Text] [Related]
34. Platinum-Coordinated Dual-Responsive Nanogels for Universal Drug Delivery and Combination Cancer Therapy.
Duan QY; Zhu YX; Jia HR; Guo Y; Zhang X; Gu R; Li C; Wu FG
Small; 2022 Nov; 18(46):e2203260. PubMed ID: 36333101
[TBL] [Abstract][Full Text] [Related]
35. Forchlorfenuron and Novel Analogs Cause Cytotoxic Effects in Untreated and Cisplatin-Resistant Malignant Mesothelioma-Derived Cells.
Henzi T; Diep KL; Oberson A; Salicio V; Bochet CG; Schwaller B
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409322
[TBL] [Abstract][Full Text] [Related]
36. 2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.
Gerogianni I; Pitaraki E; Jagirdar RM; Kouliou O; Giannakou L; Giannopoulos S; Papazoglou E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
Anticancer Res; 2019 Jul; 39(7):3809-3814. PubMed ID: 31262908
[TBL] [Abstract][Full Text] [Related]
37. pH sensitive polymeric complex of cisplatin with hyaluronic acid exhibits tumor-targeted delivery and improved in vivo antitumor effect.
Fan X; Zhao X; Qu X; Fang J
Int J Pharm; 2015 Dec; 496(2):644-53. PubMed ID: 26529576
[TBL] [Abstract][Full Text] [Related]
38. Synthesis by AGET ATRP of degradable nanogel precursors for in situ formation of nanostructured hyaluronic acid hydrogel.
Bencherif SA; Washburn NR; Matyjaszewski K
Biomacromolecules; 2009 Sep; 10(9):2499-507. PubMed ID: 19711888
[TBL] [Abstract][Full Text] [Related]
39. Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.
Dell'Anno I; Martin SA; Barbarino M; Melani A; Silvestri R; Bottaro M; Paolicchi E; Corrado A; Cipollini M; Melaiu O; Giordano A; Luzzi L; Gemignani F; Landi S
Invest New Drugs; 2021 Jun; 39(3):644-657. PubMed ID: 33300108
[TBL] [Abstract][Full Text] [Related]
40. Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network.
Li Q; Wang W; Yamada T; Matsumoto K; Sakai K; Bando Y; Uehara H; Nishioka Y; Sone S; Iwakiri S; Itoi K; Utsugi T; Yasumoto K; Yano S
Am J Pathol; 2011 Sep; 179(3):1483-93. PubMed ID: 21763682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
